Aop:138
Title: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality
AOP: Inhibition, organic anion transporter 1 (OAT1) --> Increased, blood uric acid concentration --> Occurrence, tophi (urate) deposition --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Aop:57
Title: AhR activation leading to hepatic steatosis
AOP: Activation, AhR --> Up Regulation, CD36 --> Increased, FA Influx --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:41
Title: Sustained AhR Activation leading to Rodent Liver Tumours
AOP: Activation, Long term AHR receptor driven direct and indirect gene expression changes --> Changes/Inhibition, Cellular Homeostasis and Apoptosis --> N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects --> Alterations, Cellular proliferation / hyperplasia --> Formation, Hepatocellular and Bile duct tumors

Answer: liver toxicity


Aop:177
Title: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
AOP: Inhibition, Cyclooxygenase 1 activity --> Decreased, Prostaglandin F2alpha concentration, plasma --> Occurrence, renal ischemia --> Oxidative Stress --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Aop:494
Title: AhR activation leading to liver fibrosis
AOP: Activation, AhR --> Increased, Liver Steatosis --> Increase, Cell injury/death --> Activation, Stellate cells --> Increased, extracellular matrix deposition --> N/A, Liver fibrosis

Answer: liver toxicity


Answer: liver toxicity


Aop:384
Title: Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease
AOP: Hyperactivation of ACE/Ang-II/AT1R axis --> Increased Angiotensin II --> Increased Ang II type 1 receptor (AT1R) --> Increase, Reactive oxygen species --> Increased Sodium-sensitive hypertension --> Chronic kidney disease

Answer: kidney toxicity


Answer: liver toxicity


Aop:130
Title: Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity
AOP: Inhibition, Phospholipase A --> Damage, Lipid bilayer --> Occurrence, Cytoplasmic vacuolization (hepatocyte) --> Induction, Microvesicular fat --> Formation, Liver fibrosis

Aop:318
Title: Glucocorticoid Receptor activation leading to hepatic steatosis
AOP: Activation, Glucocorticoid Receptor --> Decrease, Acyl-CoA dehydrogenases --> Decreased, Mitochondrial Fatty Acid Beta Oxidation --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Aop:36
Title: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
AOP: Decreased, PPARg activation --> Decreased, HSD17B10 expression --> Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Answer: kidney toxicity

Answer: liver toxicity


Answer: kidney toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Aop:34
Title: LXR activation leading to hepatic steatosis
AOP: Activation, LXR --> Up Regulation, CD36 --> Increase, FA Influx --> Accumulation, Triglyceride --> Mitochondrial dysfunction --> N/A, Liver Steatosis

Aop:58
Title: NR1I3 (CAR) suppression leading to hepatic steatosis
AOP: Activation, LXR --> Activation, SREBF1 --> Up Regulation, SCD-1 --> Increased, Triglyceride formation --> Increased, Liver Steatosis

Aop:518
Title: Liver X Receptor (LXR) activation leads to liver steatosis
AOP: Activation, LXR --> Increased, Expression of LXR activated genes --> Synthesis, De Novo Fatty Acid (FA) --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: kidney toxicity


Aop:554
Title: β-adrenergic receptor agonists leading to arrhythmias.
AOP: Activation, beta-2 adrenergic receptor -->  Increased Intracellular cAMP Levels --> Increased the delayed and early afterdepolarizations --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity


Aop:559
Title: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
AOP: Acetylcholinesterase (AchE) Inhibition --> Increased Muscarinic Acetylcholine Receptors --> Altered, Action Potential --> Increased delay in heart electrical conduction --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity


Aop:555
Title: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
AOP: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel --> Prolongation of Action Potential Duration --> Prolongation of QT interval --> Increased the early premature depolarizations during repolarization --> Heart failure

Answer: cardiotoxicity


Aop:61
Title: NFE2L2/FXR activation leading to hepatic steatosis
AOP: Activation, NRF2 --> Activation, NR1H4 --> Activation, PPARα --> Activation, LXR alpha --> Increased, De Novo FA synthesis --> Increased, Liver Steatosis

Aop:36
Title: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
AOP: Decreased, PPARa activation --> Decreased, HSD17B10 expression --> Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:58
Title: NR1I3 (CAR) suppression leading to hepatic steatosis
AOP: Inhibition, PPARa --> Inhibition, Mitochondrial fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Triglyceride formation --> Increased, Liver Steatosis

Aop:37
Title: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents
AOP: Activation, PPARa --> Increase, Phenotypic enzyme activity --> Increase, cell proliferation (hepatocytes) --> Increase, Clonal Expansion of Altered Hepatic Foci --> Increase, hepatocellular adenomas and carcinomas

Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Aop:57
Title: AhR activation leading to hepatic steatosis
AOP: Activation, AhR --> Up Regulation, CD36 --> Increased, FA Influx --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:41
Title: Sustained AhR Activation leading to Rodent Liver Tumours
AOP: Activation, Long term AHR receptor driven direct and indirect gene expression changes --> Changes/Inhibition, Cellular Homeostasis and Apoptosis --> N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects --> Alterations, Cellular proliferation / hyperplasia --> Formation, Hepatocellular and Bile duct tumors

Aop:177
Title: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
AOP: Inhibition, Cyclooxygenase 1 activity --> Decreased, Prostaglandin F2alpha concentration, plasma --> Occurrence, renal ischemia --> Oxidative Stress --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity

Answer: liver toxicity


Aop:138
Title: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality
AOP: Inhibition, organic anion transporter 1 (OAT1) --> Increased, blood uric acid concentration --> Occurrence, tophi (urate) deposition --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Answer: kidney toxicity


Aop:553
Title: Inhibition of Voltage-gated sodium channels (Na⁺ channels)  leading to heart failure
AOP: Inhibition, sodium channel --> Altered, Action Potential --> Decrease, Cardiac contractility --> Heart failure

Answer: cardiotoxicity


Answer: liver toxicity


Aop:220
Title: Cyp2E1 Activation Leading to Liver Cancer
AOP: Activation of Cyp2E1 --> Oxidative Stress --> Hepatocytotoxicity --> Induction, persistent proliferation/sustained proliferation --> Liver Cancer

Answer: liver toxicity


Answer: kidney toxicity


Aop:61
Title: NFE2L2/FXR activation leading to hepatic steatosis
AOP: Activation, NR1H4 --> Activation, PPARα --> Activation, LXR alpha --> Increased, De Novo FA synthesis --> Increased, Liver Steatosis

Aop:60
Title: NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis
AOP: Activation, PXR/SXR --> Inhibition, FoxA2 --> Down Regulation, CPT1A --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:517
Title: Pregnane X Receptor (PXR) activation leads to liver steatosis
AOP: Activation, Pregnane-X receptor, NR1l2 --> Up Regulation, CD36 --> Increase, FA Influx --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: cardiotoxicity


Aop:558
Title: Phosphodiesterase inhibition leading to heart failure
AOP: Phosphodiesterase inhibition --> Increased, cyclic adenosine monophosphate --> Hyperphosphorylation of ryanodine receptor (RyR2) --> Increased, Intracellular Calcium overload --> Decrease, Cardiac contractility --> Heart failure

Answer: cardiotoxicity


Answer: kidney toxicity


Answer: cardiotoxicity

Answer: liver toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: kidney toxicity

Answer: cardiotoxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Answer: kidney toxicity

Answer: liver toxicity


Aop:318
Title: Glucocorticoid Receptor activation leading to hepatic steatosis
AOP: Activation, Glucocorticoid Receptor --> Decrease, Acyl-CoA dehydrogenases --> Decreased, Mitochondrial Fatty Acid Beta Oxidation --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: liver toxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: kidney toxicity


Aop:554
Title: β-adrenergic receptor agonists leading to arrhythmias.
AOP: Activation, beta-2 adrenergic receptor -->  Increased Intracellular cAMP Levels --> Increased the delayed and early afterdepolarizations --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Aop:555
Title: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
AOP: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel --> Prolongation of Action Potential Duration --> Prolongation of QT interval --> Increased the early premature depolarizations during repolarization --> Heart failure

Answer: cardiotoxicity


Answer: kidney toxicity

Answer: cardiotoxicity


Answer: liver toxicity


Answer: kidney toxicity


Aop:559
Title: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
AOP: Acetylcholinesterase (AchE) Inhibition --> Increased Muscarinic Acetylcholine Receptors --> Altered, Action Potential --> Increased delay in heart electrical conduction --> Occurrence, cardiac arrhythmia

Answer: kidney toxicity

Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Aop:384
Title: Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease
AOP: Hyperactivation of ACE/Ang-II/AT1R axis --> Increased Angiotensin II --> Increased Ang II type 1 receptor (AT1R) --> Increase, Reactive oxygen species --> Increased Sodium-sensitive hypertension --> Chronic kidney disease

Answer: kidney toxicity

Answer: cardiotoxicity


Answer: cardiotoxicity


Aop:36
Title: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
AOP: Decreased, PPARa activation --> Decreased, HSD17B10 expression --> Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:58
Title: NR1I3 (CAR) suppression leading to hepatic steatosis
AOP: Inhibition, PPARa --> Inhibition, Mitochondrial fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Triglyceride formation --> Increased, Liver Steatosis

Aop:37
Title: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents
AOP: Activation, PPARa --> Increase, Phenotypic enzyme activity --> Increase, cell proliferation (hepatocytes) --> Increase, Clonal Expansion of Altered Hepatic Foci --> Increase, hepatocellular adenomas and carcinomas

Answer: liver toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: kidney toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Aop:130
Title: Phospholipase A2 (LPLA2) inhibitors leading to hepatotoxicity
AOP: Inhibition, Phospholipase A --> Damage, Lipid bilayer --> Occurrence, Cytoplasmic vacuolization (hepatocyte) --> Induction, Microvesicular fat --> Formation, Liver fibrosis

Aop:61
Title: NFE2L2/FXR activation leading to hepatic steatosis
AOP: Activation, NRF2 --> Activation, NR1H4 --> Activation, PPARα --> Activation, LXR alpha --> Increased, De Novo FA synthesis --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Aop:177
Title: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
AOP: Inhibition, Cyclooxygenase 1 activity --> Decreased, Prostaglandin F2alpha concentration, plasma --> Occurrence, renal ischemia --> Oxidative Stress --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: liver toxicity


Aop:138
Title: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality
AOP: Inhibition, organic anion transporter 1 (OAT1) --> Increased, blood uric acid concentration --> Occurrence, tophi (urate) deposition --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity

Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: liver toxicity


Aop:494
Title: AhR activation leading to liver fibrosis
AOP: Activation, AhR --> Increased, Liver Steatosis --> Increase, Cell injury/death --> Activation, Stellate cells --> Increased, extracellular matrix deposition --> N/A, Liver fibrosis

Aop:57
Title: AhR activation leading to hepatic steatosis
AOP: Activation, AhR --> Up Regulation, CD36 --> Increased, FA Influx --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Aop:41
Title: Sustained AhR Activation leading to Rodent Liver Tumours
AOP: Activation, Long term AHR receptor driven direct and indirect gene expression changes --> Changes/Inhibition, Cellular Homeostasis and Apoptosis --> N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects --> Alterations, Cellular proliferation / hyperplasia --> Formation, Hepatocellular and Bile duct tumors

Answer: liver toxicity


Answer: cardiotoxicity


Answer: kidney toxicity

Answer: liver toxicity


Answer: kidney toxicity


Answer: kidney toxicity

Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: cardiotoxicity


Aop:60
Title: NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis
AOP: Activation, PXR/SXR --> Inhibition, FoxA2 --> Down Regulation, CPT1A --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:517
Title: Pregnane X Receptor (PXR) activation leads to liver steatosis
AOP: Activation, Pregnane-X receptor, NR1l2 --> Up Regulation, CD36 --> Increase, FA Influx --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: cardiotoxicity


Aop:558
Title: Phosphodiesterase inhibition leading to heart failure
AOP: Phosphodiesterase inhibition --> Increased, cyclic adenosine monophosphate --> Hyperphosphorylation of ryanodine receptor (RyR2) --> Increased, Intracellular Calcium overload --> Decrease, Cardiac contractility --> Heart failure

Answer: cardiotoxicity


Answer: liver toxicity


Aop:318
Title: Glucocorticoid Receptor activation leading to hepatic steatosis
AOP: Activation, Glucocorticoid Receptor --> Decrease, Acyl-CoA dehydrogenases --> Decreased, Mitochondrial Fatty Acid Beta Oxidation --> Accumulation, Triglyceride --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: liver toxicity


Aop:61
Title: NFE2L2/FXR activation leading to hepatic steatosis
AOP: Activation, NR1H4 --> Activation, PPARα --> Activation, LXR alpha --> Increased, De Novo FA synthesis --> Increased, Liver Steatosis

Aop:554
Title: β-adrenergic receptor agonists leading to arrhythmias.
AOP: Activation, beta-2 adrenergic receptor -->  Increased Intracellular cAMP Levels --> Increased the delayed and early afterdepolarizations --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity

Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Aop:555
Title: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
AOP: Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel --> Prolongation of Action Potential Duration --> Prolongation of QT interval --> Increased the early premature depolarizations during repolarization --> Heart failure

Answer: cardiotoxicity


Answer: liver toxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity

Answer: liver toxicity


Answer: cardiotoxicity


Aop:559
Title: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
AOP: Acetylcholinesterase (AchE) Inhibition --> Increased Muscarinic Acetylcholine Receptors --> Altered, Action Potential --> Increased delay in heart electrical conduction --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity


Aop:36
Title: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
AOP: Decreased, PPARa activation --> Decreased, HSD17B10 expression --> Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Aop:58
Title: NR1I3 (CAR) suppression leading to hepatic steatosis
AOP: Inhibition, PPARa --> Inhibition, Mitochondrial fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Triglyceride formation --> Increased, Liver Steatosis

Aop:37
Title: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents
AOP: Activation, PPARa --> Increase, Phenotypic enzyme activity --> Increase, cell proliferation (hepatocytes) --> Increase, Clonal Expansion of Altered Hepatic Foci --> Increase, hepatocellular adenomas and carcinomas

Answer: liver toxicity


Answer: kidney toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Aop:61
Title: NFE2L2/FXR activation leading to hepatic steatosis
AOP: Activation, NRF2 --> Activation, NR1H4 --> Activation, PPARα --> Activation, LXR alpha --> Increased, De Novo FA synthesis --> Increased, Liver Steatosis

Answer: liver toxicity


Aop:36
Title: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis
AOP: Decreased, PPARb activation --> Decreased, HSD17B10 expression --> Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity --> Decrease, Fatty acid beta-oxidation --> Accumulation, Fatty acid --> Increased, Liver Steatosis

Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: liver toxicity


Answer: cardiotoxicity


Aop:138
Title: Organic anion transporter (OAT1) inhibition leading to renal failure and mortality
AOP: Inhibition, organic anion transporter 1 (OAT1) --> Increased, blood uric acid concentration --> Occurrence, tophi (urate) deposition --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Answer: cardiotoxicity


Aop:553
Title: Inhibition of Voltage-gated sodium channels (Na⁺ channels)  leading to heart failure
AOP: Inhibition, sodium channel --> Altered, Action Potential --> Decrease, Cardiac contractility --> Heart failure

Aop:562
Title: HCN Channel Inhibition leading to Arrhythmias
AOP: HCN Channel Inhibition --> Reduced Pacemaker Activity in SA Node --> Slowed Heart Rate --> Altered Cardiac Electrical Conduction --> Occurrence, cardiac arrhythmia

Answer: cardiotoxicity


Aop:220
Title: Cyp2E1 Activation Leading to Liver Cancer
AOP: Activation of Cyp2E1 --> Oxidative Stress --> Hepatocytotoxicity --> Induction, persistent proliferation/sustained proliferation --> Liver Cancer

Answer: liver toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity

Answer: liver toxicity


Aop:177
Title: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
AOP: Inhibition, Cyclooxygenase 1 activity --> Decreased, Prostaglandin F2alpha concentration, plasma --> Occurrence, renal ischemia --> Oxidative Stress --> Occurrence, renal proximal tubular necrosis --> Increased, blood potassium concentration --> Occurrence, cardiac arrhythmia --> Increased Mortality

Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: liver toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: kidney toxicity

Answer: liver toxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: kidney toxicity


Answer: cardiotoxicity


Answer: cardiotoxicity


Answer: kidney toxicity

Answer: cardiotoxicity


Answer: kidney toxicity


Answer: cardiotoxicity